Cargando…

The H/R FcγRIIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population

Detalles Bibliográficos
Autores principales:	Levy, Débora, Bellesso, Marcelo, Oliveira-Souza, Pamela, Maciel, Felipe V., Pereira, Juliana, Bydlowski, Sérgio P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2011
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109397/ https://www.ncbi.nlm.nih.gov/pubmed/21789402 http://dx.doi.org/10.1590/S1807-59322011000500034

Ejemplares similares

Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131)
por: Mimoto, F., et al.
Publicado: (2013)

Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression
por: Bournazos, Stylianos, et al.
Publicado: (2010)

Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2
por: Wines, Bruce D., et al.
Publicado: (2021)

The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1
por: Anania, Jessica C., et al.
Publicado: (2018)

A tail of two ITAMs: GPVI/FcRγ and FcγRIIa's role in platelet activation and thrombus stability
por: Neeves, Keith B.
Publicado: (2021)

FcγRIIa and FcγRIIIa genes polymorphism in Egyptian children with primary immune thrombocytopenia
por: Zakaria, Marwa, et al.
Publicado: (2023)

DLBCL 1L—What to Expect beyond R-CHOP?
por: Stegemann, Maike, et al.
Publicado: (2022)

FcγRIIa defunctioning polymorphism in paediatric patients with renal allograft
por: Fadel, Fatina I., et al.
Publicado: (2017)

Analysis of HLA DR, HLA DQ, C4A, FcγRIIa, FcγRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcγRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility
por: Jönsen, Andreas, et al.
Publicado: (2004)

Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL
por: Lancman, Guido, et al.
Publicado: (2018)

Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL
por: Hartert, Keenan T., et al.
Publicado: (2020)

The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
por: ROŽMAN, SAMO, et al.
Publicado: (2016)

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
por: de Jonge, A. Vera, et al.
Publicado: (2023)

Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19
por: Apostolidis, Sokratis A., et al.
Publicado: (2022)

Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19
por: Apostolidis, Sokratis A., et al.
Publicado: (2021)

Neutrophil FcγRIIA availability is associated with disease activity in systemic lupus erythematosus
por: Bengtsson, Anders A., et al.
Publicado: (2020)

Endothelial Shear Stress and Platelet FcγRIIa Expression in Intracranial Atherosclerotic Disease
por: Liebeskind, David S., et al.
Publicado: (2021)

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
por: Ayed, Ayed O., et al.
Publicado: (2018)

Predictive Value of Interim PET/CT in DLBCL Treated with R-CHOP: Meta-Analysis
por: Sun, Na, et al.
Publicado: (2015)

CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance
por: Qiao, Li-Yan, et al.
Publicado: (2021)

Cancer cell-derived immunoglobulin G activates platelets by binding to platelet FcγRIIa
por: Miao, Shuo, et al.
Publicado: (2019)

A subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation
por: Rijkers, Maaike, et al.
Publicado: (2018)

Inhibitory affinity modulation of FcγRIIA ligand binding by glycosphingolipids by inside-out signaling
por: Okubo, Koshu, et al.
Publicado: (2021)

Spontaneous Platelet Aggregation in Blood Is Mediated by FcγRIIA Stimulation of Bruton’s Tyrosine Kinase
por: Duan, Rundan, et al.
Publicado: (2021)

FcγRIIA-specific DARPins as novel tools in blood cell analysis and platelet aggregation
por: Riechert, Vanessa, et al.
Publicado: (2023)

The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease
por: Chang, Ling-Sai, et al.
Publicado: (2016)

Disease progression after R-CHOP treatment associated with the loss of CD20 antigen expression
por: Bellesso, Marcelo, et al.
Publicado: (2011)

Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI
por: Bohländer, Fabian, et al.
Publicado: (2021)

Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
por: Herrmann, Ken, et al.
Publicado: (2014)

CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL
por: Bouroumeau, Antonin, et al.
Publicado: (2021)

Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP
por: Dong, Qian, et al.
Publicado: (2022)

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
por: Geng, Hongzhi, et al.
Publicado: (2023)

FcγRIIA and IIIA polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer
por: Wang, De-shen, et al.
Publicado: (2017)

Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses
por: Chen, Bo, et al.
Publicado: (2019)

Cytoskeleton Dependent Mobility Dynamics of FcγRIIA Facilitates Platelet Haptotaxis and Capture of Opsonized Bacteria
por: Palankar, Raghavendra, et al.
Publicado: (2022)

Factor VIII Fc Fusion Protein but not FVIII Drives Human Monocyte-Derived Dendritic Cell Activation via FcγRIIa
por: Kannicht, Christoph, et al.
Publicado: (2020)

Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP–treated DLBCL
por: Bouroumeau, Antonin, et al.
Publicado: (2021)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
por: Zhu, H., et al.
Publicado: (2022)

Significant differences in FcγRIIa, FcγRIIIa and FcγRIIIb genes polymorphism and anti-malarial IgG subclass pattern are associated with severe Plasmodium falciparum malaria in Saudi children
por: Nasr, Amre, et al.
Publicado: (2021)

Development of a Cell-Based Assay Measuring the Activation of FcγRIIa for the Characterization of Therapeutic Monoclonal Antibodies
por: Tada, Minoru, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ovloaq15fg9lqjfcocnem58pti